Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy
We present a case of metastatic prostate cancer with rare metastases involving the brain and orbit, in addition to liver, skeletal and nodal metastases. The patient had undergone prior hormonal therapy and chemotherapy and had disease progression despite 2 cycles of 177Lu-Prostate specific membrane...
Main Authors: | Ashwin Singh Parihar, Kunal Chandekar, Harpreet Singh, Ashwani Sood, Bhagwant Mittal |
---|---|
Format: | Article |
Language: | English |
Published: |
Mashhad University of Medical Sciences
2021-01-01
|
Series: | Asia Oceania Journal of Nuclear Medicine and Biology |
Subjects: | |
Online Access: | https://aojnmb.mums.ac.ir/article_16769_413113d44db458fbafbe7be4fd8a6828.pdf |
Similar Items
-
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01) -
Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01) -
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024-02-01) -
An exceptional response to 177LuPSMA undermined by neuroendocrine transformation
by: Pretoria Bilinski, et al.
Published: (2021-01-01) -
Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
by: Jan Heilinger, et al.
Published: (2023-09-01)